Wealth Enhancement Advisory Services LLC Boosts Stake in Takeda Pharmaceutical Co. $TAK

Wealth Enhancement Advisory Services LLC grew its stake in Takeda Pharmaceutical Co. (NYSE:TAK) by 1.8% in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 67,649 shares of the company’s stock after buying an additional 1,174 shares during the period. Wealth Enhancement Advisory Services LLC’s holdings in Takeda Pharmaceutical were worth $1,038,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also made changes to their positions in TAK. FNY Investment Advisers LLC purchased a new position in shares of Takeda Pharmaceutical in the first quarter worth $37,000. Farther Finance Advisors LLC raised its holdings in shares of Takeda Pharmaceutical by 29.2% in the first quarter. Farther Finance Advisors LLC now owns 4,620 shares of the company’s stock worth $69,000 after buying an additional 1,045 shares during the last quarter. Fifth Third Bancorp raised its holdings in shares of Takeda Pharmaceutical by 85.5% in the first quarter. Fifth Third Bancorp now owns 5,232 shares of the company’s stock worth $78,000 after buying an additional 2,411 shares during the last quarter. GAMMA Investing LLC raised its holdings in shares of Takeda Pharmaceutical by 22.6% in the first quarter. GAMMA Investing LLC now owns 7,042 shares of the company’s stock worth $105,000 after buying an additional 1,296 shares during the last quarter. Finally, Caitong International Asset Management Co. Ltd purchased a new position in shares of Takeda Pharmaceutical in the first quarter worth $125,000. Hedge funds and other institutional investors own 9.17% of the company’s stock.

Analyst Upgrades and Downgrades

Separately, Zacks Research cut shares of Takeda Pharmaceutical from a “hold” rating to a “strong sell” rating in a report on Thursday, August 21st. One research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, Takeda Pharmaceutical currently has a consensus rating of “Hold”.

Takeda Pharmaceutical Stock Up 0.8%

TAK stock opened at $14.76 on Thursday. The firm has a market cap of $46.95 billion, a PE ratio of 49.18 and a beta of 0.21. The company has a debt-to-equity ratio of 0.60, a quick ratio of 0.59 and a current ratio of 1.16. The firm’s fifty day moving average is $14.84 and its 200 day moving average is $14.83. Takeda Pharmaceutical Co. has a one year low of $12.80 and a one year high of $15.69.

Takeda Pharmaceutical (NYSE:TAK) last released its quarterly earnings results on Wednesday, July 30th. The company reported $0.52 EPS for the quarter, beating the consensus estimate of $0.47 by $0.05. The company had revenue of $7.45 billion for the quarter, compared to analyst estimates of $7.96 billion. Takeda Pharmaceutical had a net margin of 3.20% and a return on equity of 10.50%. Takeda Pharmaceutical has set its FY 2025 guidance at 3.360-3.360 EPS. On average, research analysts forecast that Takeda Pharmaceutical Co. will post 1.64 EPS for the current year.

Takeda Pharmaceutical Profile

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.